Jun 01, 2020
Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Apr 29, 2020
UCB's Cimzia is Making Inroads in the Treatment of Axial Disease, with Significant Uptake in Non-Radiographic Axial Spondyloarthritis and a Positive Treatment Halo in Ankylosing Spondylitis
Nov 12, 2019
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
Oct 24, 2019
Ankylosing Spondylitis; Understanding this Chronic Inflammatory Joint Disorder
Oct 02, 2019
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
May 02, 2019
Spondylitis Association of America Launches Global Spondyloarthritis Summit to Raise Awareness of Painful Rheumatic Disease
Apr 22, 2019
Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
Aug 08, 2018
Spondyloarthritis Resource Center Provides Information And Tips For Dealing With Chronic Back And Joint Pain
Feb 13, 2018
Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Nov 16, 2017
Global Rheumatoid Arthritis Epidemiology and Patient Flow Analysis - 2017
Oct 26, 2017
What Matters Most to Canadians Living with Rheumatoid Arthritis?